These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

3489 related items for PubMed ID: 19637230

  • 1. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR, Holst PJ, Pircher H, Christensen JP, Thomsen AR.
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [Abstract] [Full Text] [Related]

  • 2. Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain.
    Mikkelsen M, Holst PJ, Bukh J, Thomsen AR, Christensen JP.
    J Immunol; 2011 Feb 15; 186(4):2355-64. PubMed ID: 21257961
    [Abstract] [Full Text] [Related]

  • 3. Superior tumor protection induced by a cellular vaccine carrying a tumor-specific T helper epitope by genetic exchange of the class II-associated invariant chain peptide.
    van Bergen J, Camps M, Offringa R, Melief CJ, Ossendorp F, Koning F.
    Cancer Res; 2000 Nov 15; 60(22):6427-33. PubMed ID: 11103809
    [Abstract] [Full Text] [Related]

  • 4. Adenovirus-based vaccine against Listeria monocytogenes: extending the concept of invariant chain linkage.
    Jensen S, Steffensen MA, Jensen BA, Schlüter D, Christensen JP, Thomsen AR.
    J Immunol; 2013 Oct 15; 191(8):4152-64. PubMed ID: 24043891
    [Abstract] [Full Text] [Related]

  • 5. CD4+ TH1 cells generated by Ii-PADRE DNA at prime phase are important to induce effectors and memory CD8+ T cells.
    Park JY, Jin DH, Lee CM, Jang MJ, Lee SY, Shin HS, Chung YH, Kim KY, Kim SS, Lee WB, Shin YK, Lee WJ, Park YM, Kim D.
    J Immunother; 2010 Jun 15; 33(5):510-22. PubMed ID: 20463596
    [Abstract] [Full Text] [Related]

  • 6. MHC class II-associated invariant chain linkage of antigen dramatically improves cell-mediated immunity induced by adenovirus vaccines.
    Holst PJ, Sorensen MR, Mandrup Jensen CM, Orskov C, Thomsen AR, Christensen JP.
    J Immunol; 2008 Mar 01; 180(5):3339-46. PubMed ID: 18292559
    [Abstract] [Full Text] [Related]

  • 7. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
    Teramoto K, Kontani K, Ozaki Y, Sawai S, Tezuka N, Nagata T, Fujino S, Itoh Y, Taguchi O, Koide Y, Asai T, Ohkubo I, Ogasawara K.
    Cancer Res; 2003 Nov 15; 63(22):7920-5. PubMed ID: 14633722
    [Abstract] [Full Text] [Related]

  • 8. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D, Dubey S, Van Veldhuizen P, Holzbeierlein JM, Tawfik O, Thrasher JB.
    Immunotherapy; 2011 Jun 15; 3(6):735-46. PubMed ID: 21668311
    [Abstract] [Full Text] [Related]

  • 9. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.
    Tüting T, Steitz J, Brück J, Gambotto A, Steinbrink K, DeLeo AB, Robbins P, Knop J, Enk AH.
    J Gene Med; 1999 Jun 15; 1(6):400-6. PubMed ID: 10753065
    [Abstract] [Full Text] [Related]

  • 10. [Ad hTRP2 - mediated immunity against melanoma is enhanced by dendritic cells pulsed with peptide].
    Tan XH, Liu C, Wan YH.
    Zhonghua Zhong Liu Za Zhi; 2006 Sep 15; 28(9):658-61. PubMed ID: 17274369
    [Abstract] [Full Text] [Related]

  • 11. Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model.
    Sorensen MR, Holst PJ, Steffensen MA, Christensen JP, Thomsen AR.
    Vaccine; 2010 Sep 24; 28(41):6757-64. PubMed ID: 20682365
    [Abstract] [Full Text] [Related]

  • 12. Generation of a prophylactic melanoma vaccine using whole recombinant yeast expressing MART-1.
    Riemann H, Takao J, Shellman YG, Hines WA, Edwards CK, Franzusoff A, Norris DA, Fujita M.
    Exp Dermatol; 2007 Oct 24; 16(10):814-22. PubMed ID: 17845213
    [Abstract] [Full Text] [Related]

  • 13. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo.
    Prévost-Blondel A, Zimmermann C, Stemmer C, Kulmburg P, Rosenthal FM, Pircher H.
    J Immunol; 1998 Sep 01; 161(5):2187-94. PubMed ID: 9725210
    [Abstract] [Full Text] [Related]

  • 14. Vaccination against lymphocytic choriomeningitis virus infection in MHC class II-deficient mice.
    Holst PJ, Christensen JP, Thomsen AR.
    J Immunol; 2011 Apr 01; 186(7):3997-4007. PubMed ID: 21357263
    [Abstract] [Full Text] [Related]

  • 15. Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin.
    Hsieh CJ, Kim TW, Hung CF, Juang J, Moniz M, Boyd DA, He L, Chen PJ, Chen CH, Wu TC.
    Vaccine; 2004 Sep 28; 22(29-30):3993-4001. PubMed ID: 15364449
    [Abstract] [Full Text] [Related]

  • 16. Pancreas carcinoma antigen fused to invariant chain elicits T-cell response and tumor growth inhibition.
    Nagaraj S, Neumann J, Winzen B, Frank S, Ziske C, Sievers E, Koch N, Schmidt-Wolf IG.
    Pancreas; 2008 Oct 28; 37(3):321-7. PubMed ID: 18815556
    [Abstract] [Full Text] [Related]

  • 17. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J.
    Clin Cancer Res; 2003 May 28; 9(5):1837-49. PubMed ID: 12738742
    [Abstract] [Full Text] [Related]

  • 18. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer.
    Garcia-Hernandez Mde L, Gray A, Hubby B, Kast WM.
    Cancer Res; 2007 Feb 01; 67(3):1344-51. PubMed ID: 17283172
    [Abstract] [Full Text] [Related]

  • 19. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S, Lee JB, Lee GK, Chang J.
    Prostate; 2009 Jun 15; 69(9):938-48. PubMed ID: 19267351
    [Abstract] [Full Text] [Related]

  • 20. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B, Simmons A, Du T, Lin C, Moskalenko M, Gonzalez-Edick M, VanRoey M, Jooss K.
    Clin Immunol; 2009 Nov 15; 133(2):184-97. PubMed ID: 19664962
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 175.